BioXcel Therapeutics (BTAI) PT Raised to $104 at BMO Capital; 'BXCL501 Clean SERENITY Data Supports Approval'
Tweet Send to a Friend
BMO Capital analyst Do Kim raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $104.00 (from $64.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
